zipalertinib (CLN-081) / Cullinan Therap, Otsuka 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   0 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zipalertinib (CLN-081) / Cullinan Therap, Otsuka
REZILIENT3, NCT05973773: (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Recruiting
3
272
Europe, Canada, Japan, US, RoW
TAS6417, Zipalertinib, CLN-081
Taiho Oncology, Inc.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
07/26
08/26
REZILIENT2, NCT05967689: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Active, not recruiting
2
160
Europe, Canada, Japan, US, RoW
TAS6417, CLN-081, zipalertinib
Taiho Oncology, Inc.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
06/25
10/25
2019-002409-23: Phase 1/2 Study of CLN-081 in Patients with Lung Cancer

Not yet recruiting
1/2
369
Europe
CLN-081, Film-coated tablet
Cullinan Oncology Inc., Cullinan Oncology Inc.
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Niet-kleincellige longkanker met EGFR-exon 20-invoegingsmutaties, Lung Cancer Longkanker, Diseases [C] - Cancer [C04]
 
 
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24

Download Options